Lilly helps Circle round up $66M for intractable target R&D ntaylor Thu, 06/17/2021 - 06:01.: Register for the FierceBiotech Virtual Series, Next Gen: What's Beyond the Leading Edge of Biotech and Pharma? Join us June 22–23 as we discuss new waves of cancer targets, novel approaches to cell and gene therapies, advances in biopharma manufacturing, and more. Circle Pharma has raised $66 million to take cyclin-targeted programs toward clinical development. The Eli Lilly-backed series C round sets Circle up to build on its years of research into cell-permeable macrocyclic peptide therapeutics with the potential to hit previously undruggable targets.
In this article
No tags related to this article.